LSR Stock Chart & Stats
€1.31
€0.00(0.00%)
At close: 4:00 PM EDT
€1.31
€0.00(0.00%)
Day’s Range― - ―
52-Week Range€0.76 - €9.70
Previous CloseN/A
Volume0.00
Average Volume (3M)1.00
Market Cap
€36.09M
Enterprise Value€13.97M
Total Cash (Recent Filing)€6.53M
Total Debt (Recent Filing)€7.89M
Price to Earnings (P/E)―
Beta2.03
Next Earnings
Dec 23, 2026EPS EstimateN/A
Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)-2.58
Shares Outstanding17,588,987
10 Day Avg. Volume0
30 Day Avg. Volume1
Financial Highlights & Ratios
PEG Ratio0.03
Price to Book (P/B)2.34
Price to Sales (P/S)0.00
P/FCF Ratio-2.17
Enterprise Value/Market CapN/A
Enterprise Value/RevenueN/A
Enterprise Value/Gross ProfitN/A
Enterprise Value/EbitdaN/A
Forecast
1Y Price TargetN/A
Price Target UpsideN/A
Rating ConsensusN/A
Number of Analyst Covering0
EPS Forecast (FY)-0.81
Revenue Forecast (FY)€16.75M
Bulls Say, Bears Say
Bulls Say
CDMO Revenue OptionThe CDMO business gives Cel-Sci a service-based route to revenue alongside drug development, potentially diversifying funding sources. Contracted manufacturing and facility access can support recurring activity as customer work and milestones continue, although timing remains variable.
Focused Oncology PipelineA defined lead program in head and neck cancer gives the company a focused clinical development objective and a potential future product platform. If development succeeds, commercialization could add product revenue, though the candidate remains investigational today.
Historical Capital StructurePositive equity and historically moderate debt-to-equity provide a stronger base than a highly levered development biotech over 2021–2025. This may preserve some financing flexibility, although the TTM balance-sheet step-up materially weakens that advantage.
Bears Say
No Demonstrated RevenueZero revenue across multiple annual periods and the latest TTM confirms that Cel-Sci remains pre-commercial, with no demonstrated sales base to fund operations. This leaves future financial performance dependent on development progress, CDMO activity, or external financing.
Persistent Cash BurnConsistently negative operating and free cash flow shows that the business is not self-funding. Ongoing annual burn requires continued access to capital or other funding sources, which can constrain investment choices and increase execution risk as development work continues.
Balance-Sheet VolatilityThe sharp TTM increase in reported debt, assets, and equity creates substantial balance-sheet volatility compared with prior years. Even with TTM debt-to-equity near 0.72, the unusual step-change increases uncertainty around capital structure, financing needs, and financial stability.
Cel-Sci News
LSR FAQ
What was Cel-Sci Corp.’s price range in the past 12 months?
Cel-Sci Corp. lowest stock price was €0.76 and its highest was €9.70 in the past 12 months.
What is Cel-Sci Corp.’s market cap?
Cel-Sci Corp.’s market cap is €36.09M.
When is Cel-Sci Corp.’s upcoming earnings report date?
Cel-Sci Corp.’s upcoming earnings report date is Dec 23, 2026 which is in 80 days.
How were Cel-Sci Corp.’s earnings last quarter?
Cel-Sci Corp. released its earnings results on Aug 17, 2026. The company reported -€0.417 earnings per share for the quarter.
Is Cel-Sci Corp. overvalued?
According to Wall Street analysts Cel-Sci Corp.’s price is currently Overvalued.
Does Cel-Sci Corp. pay dividends?
Cel-Sci Corp. does not currently pay dividends.
What is Cel-Sci Corp.’s EPS estimate?
Cel-Sci Corp.’s EPS estimate for its next earnings report is not yet available.
How many shares outstanding does Cel-Sci Corp. have?
Cel-Sci Corp. has 17,588,987 shares outstanding.
What happened to Cel-Sci Corp.’s price movement after its last earnings report?
Cel-Sci Corp. reported an EPS of -€0.417 in its last earnings report. Following the earnings report the stock price went up 5.042%.
Which hedge fund is a major shareholder of Cel-Sci Corp.?
Currently, no hedge funds are holding shares in DE:LSR
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology
Cel-Sci Stock Smart Score
Underperform
1
2
3
4
5
6
7
8
9
10
Blogger Sentiment
Bearish
DE:LSR Sentiment 100%
Sector Average 65%
Sector Average 65%
Insider Transactions
Bought Shares
Worth €121.8K over
the Last 3 Months
the Last 3 Months
Technicals
SMA
Negative
20 days / 200 days
Momentum
-77.26%
12-Months-Change
Fundamentals
Return on Equity
―
Trailing 12-Months
Asset Growth
5.01%
Trailing 12-Months
Learn more about TipRanks Smart Score
Company Description
Cel-Sci Corp.
CEL-SCI Corporation (CVM) focuses on the research and development of immune-based therapies to combat cancer and various infectious diseases. Its flagship immunotherapy candidate, Multikine, is currently undergoing Phase III clinical trials for the treatment of head and neck cancer. The company also develops and holds the patent for its preclinical Ligand Epitope Antigen Presentation System (LEAPS), an innovative T-cell modulation technology. This system is designed to stimulate the human immune system to fight a broad range of conditions, including bacterial, viral, and parasitic infections, as well as autoimmune diseases, allergies, transplantation rejections, and various cancers. CEL-SCI's pipeline further includes LEAPS-H1N1-DC, along with LEAPS COV-19, an experimental therapy targeting the COVID-19 coronavirus. Additionally, the company is advancing CEL-2000 and CEL-4000 as potential treatments for rheumatoid arthritis. In a collaborative effort, CEL-SCI has partnered with the University of Georgia's Center for Vaccines and Immunology to progress the LEAPS COVID-19 immunotherapy. Established in 1983, the company's headquarters are located in Vienna, Virginia.